Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Drop in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 48,137 shares, a drop of 83.9% from the May 31st total of 298,780 shares. Based on an average daily trading volume, of 825,528 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Hold rating, According to MarketBeat, Daiichi Sankyo has an average rating of “Hold”.

Daiichi Sankyo Trading Up 0.5%

Shares of DSNKY stock traded up $0.08 during mid-day trading on Friday, reaching $15.85. 492,088 shares of the stock traded hands, compared to its average volume of 344,940. The stock’s fifty day simple moving average is $16.50 and its two-hundred day simple moving average is $18.57. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $27.50. The company has a market cap of $29.53 billion, a price-to-earnings ratio of 16.86, a price-to-earnings-growth ratio of 2.71 and a beta of -0.16. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, research analysts anticipate that Daiichi Sankyo will post 0.98 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.